Andreas Lohri
Overview
Explore the profile of Andreas Lohri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1519
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moccia A, Taverna C, Schar S, Vanazzi A, Rondeau S, Hitz F, et al.
Blood Adv
. 2020 Dec;
4(23):5951-5957.
PMID: 33275769
The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03 randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules in patients with follicular lymphoma (FL). Here, we report...
2.
Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U, et al.
Blood Adv
. 2020 Aug;
4(15):3699-3707.
PMID: 32777066
Hairy cell leukemia (HCL) remains an incurable disease. However, first-line treatment with either intravenous or subcutaneous cladribine generally leads to long-lasting remissions. Although there are excellent long-term data for intravenous...
3.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al.
J Clin Oncol
. 2019 Sep;
37(31):2835-2845.
PMID: 31498753
Purpose: Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients with early-stage favorable Hodgkin lymphoma (HL). However, the role...
4.
Zucca E, Rondeau S, Vanazzi A, Ostenstad B, Mey U, Rauch D, et al.
Blood
. 2019 May;
134(4):353-362.
PMID: 31101627
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in...
5.
Bargetzi M, Baumann R, Cogliatti S, Dietrich P, Duchosal M, Goede J, et al.
Swiss Med Wkly
. 2018 Jul;
148:w14635.
PMID: 30044476
Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life. In addition...
6.
Premstaller M, Perren M, Kocack K, Arranto C, Favre G, Lohri A, et al.
J Clin Lipidol
. 2018 Jan;
12(2):464-480.e3.
PMID: 29310991
Background: Dyslipidemia is common after hematopoietic stem cell transplantation (HSCT). Few data regarding the time course of lipid profiles after HSCT, the effect of multiple transplantations, and efficacy and safety...
7.
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, et al.
Lancet
. 2017 Oct;
390(10114):2790-2802.
PMID: 29061295
Background: The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) is very active in patients with advanced-stage Hodgkin's lymphoma, albeit at the expense...
8.
Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, et al.
Lancet Oncol
. 2017 Feb;
18(4):454-463.
PMID: 28236583
Background: Advanced stage Hodgkin's lymphoma represents a heterogeneous group of patients with different risk profiles. Data suggests that interim PET assessment during chemotherapy is superior to baseline international prognostic scoring...
9.
Lohri A
Praxis (Bern 1994)
. 2016 Jan;
105(1):47-52.
PMID: 26732717
Although malignant lymphoma is split in over 60 distinct entities, four of them, diffuse large B cell lymphoma, follicular-, Hodgkin's- and mantle cell lymphoma constitute more than half of all...
10.
Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, et al.
J Clin Oncol
. 2015 Dec;
34(5):495-500.
PMID: 26712227
Purpose: Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of maintenance treatment remains unknown. Patients And Methods: Two hundred...